Clinical Trials Logo

Leukemia, Myeloid, Acute clinical trials

View clinical trials related to Leukemia, Myeloid, Acute.

Filter by:

NCT ID: NCT03449745 Completed - Clinical trials for Acute Myeloid Leukemia

Immune Checkpoint Receptors in AML-Leukemic Initiating Cells

ICAML-LIC
Start date: May 29, 2018
Phase:
Study type: Observational

This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.

NCT ID: NCT03442452 Completed - Clinical trials for Acute Myeloid Leukemia

AML Electronic Decision Aid

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.

NCT ID: NCT03441555 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).

NCT ID: NCT03441048 Completed - Clinical trials for Acute Myeloid Leukemia

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 22, 2018
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose, recommended phase 2 dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase 2 dose.

NCT ID: NCT03435848 Completed - Clinical trials for Acute Myeloid Leukemia

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

ELPIS
Start date: August 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assesses the benefit, safety, and pharmacokinetics (PK) of BST-236 in patients with newly-diagnosed Acute Myeloid Leukemia (AML) who are not eligible for standard induction chemotherapy due to advanced age or comorbidities. The Complete Remission (CR) rate following treatment with BST-236 will be compared to the CR rate reported in historical data in a similar population.

NCT ID: NCT03435341 Completed - Clinical trials for Leukemia, Myeloid, Acute

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

Start date: February 28, 2018
Phase:
Study type: Observational

Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival related to the patient, in a prospective cohort of patients over 60 with AML diagnosis in Spain and treated outside of clinical trials; that is, under conditions of standard clinical practice. The study will last 24 months in total from the inclusion of the first patient until the end of the last patient's follow-up

NCT ID: NCT03433521 Completed - Clinical trials for Acute Myeloid Leukemia

Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia

Start date: January 1, 2018
Phase:
Study type: Observational

Published data regarding the temporal pattern of AML are scarce and old. The greater knowledge of these neoplasias has made that their classification has been remarkable modified. Therefore, we consider relevant to carry out the present study as it would allow us to analyze the potential existence of a spatio-temporal pattern in the incidence of AML in Spain.

NCT ID: NCT03426605 Completed - Clinical trials for Acute Myeloid Leukemia

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Start date: January 16, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

NCT ID: NCT03417154 Completed - Clinical trials for Acute Myeloid Leukemia

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a randomized pilot sub-study during stage 1.

NCT ID: NCT03416179 Completed - Clinical trials for Leukemia, Myeloid, Acute

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

BRIGHT AML1019
Start date: April 20, 2018
Phase: Phase 3
Study type: Interventional

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).